Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) filed patent applications in multiple countries for a group of compounds called “Family 6” that are not hallucinogenic and are designed to be better versions of existing psychedelic and nonpsychedelic drugs, according to a statement from the company.
By making the drugs nonhallucinogenic, the company aims to help a larger group of people, including children and older adults, as these drugs won’t cause the mind-altering effects often associated with psychedelics.
This would also make treatment more convenient, as patients wouldn’t need to be supervised during treatment.
“By reducing or removing the psychedelic effect, in-clinic supervision should not be necessary, in turn reducing cost and improving convenience of these treatment options,” CEO James Lanthier said in a statement.
“They’re going to work better as (mental-health) medicines; they’ll be safer, more predictable, have potentially different durations,” he added.
With multiple psychedelic drug candidates advancing well, @MindsetPharma is now making a major discovery push into novel non-hallucinogenic drugs. We are excited about the patient groups and indications that this class of drugs can potentially serve. https://t.co/XAITRcgXrq
— James Lanthier (@JamesLanthier) March 28, 2023
The company has completed pre-clinical studies on the non-tryptamine compounds from Family 6, which have shown positive results. The drugs have been tested in several ways, including in-vitro screening, ADME evaluation, and in vivo studies, to assess their benefits and safety before moving to clinical trials.
- In-vitro screening: Laboratory tests conducted in a controlled environment outside a living organism, like in a test tube or petri dish.
- ADME: Evaluating how the drug is absorbed, distributed, metabolized, and excreted by the body.
- In vivo studies: Tests performed on living organisms, such as animals, to understand how the drug works in a real-life situation.
The compounds have been found to activate the 5-HT2A serotonin receptor without causing hallucinations. This receptor is involved in various brain functions and has been a target for treating neuropsychiatric and neurological disorders. The compounds can interact with this receptor without creating the unwanted side effects that hallucinogenic drugs typically cause.
Some Family 6 compounds are more potent than psilocybin and 5-MeO-DMT as 5-HT2A agonists, but these drug candidates elicited only a modest or no head twitch response, suggesting a non-hallucinogenic effect profile.
The patent applications will protect Mindset’s rights to its nonhallucinogenic non-tryptamine compounds from Family 6, a significant step toward its goal to develop new medicines to help people with brain-related disorders for which there are currently no true effective treatments.
The post Mindset Pharma Files Patents for Nonhallucinogenic Psychedelic Drugs to Treat Brain Disorders appeared first on Green Market Report.psilocybin dmt psychedelic serotonin hallucinogenic psychedelics cse mindset pharma mindset
Law & Regulation3 days ago
Psilocybin study for bipolar depression encourages more research
Psilocybin3 days ago
Magic Mushroom Edibles: Everything to Know, from Chocolates to Drops
LSD4 days ago
TECH HEAVY: The Magnificent Seven has suddenly become the Fantastic Four
Ketamine3 days ago
Prepping the psychedelic industry for MDMA approval
Psychedelics3 days ago
Psychedelics Effects on Sexual Functions
Law & Regulation2 days ago
Enveric sells cannabis patents to focus on psilocin candidates